Biopharmaceutical Fermentation System Market to Grow with a CAGR of 8.67% through 2031
Increasing demand for biopharmaceuticals,
technological advancements, and outsourcing trends are expected to drive the
Global Biopharmaceutical Fermentation System Market growth in the forecast
period, 2021-2031F
According to TechSci Research report, “Biopharmaceutical Fermentation System Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2031”, the Global Biopharmaceutical Fermentation System Market will grow from USD 27.68 Billion in 2025 to USD 45.59 Billion by 2031 at an 8.67% CAGR. This can be attributed to regulatory support and compliance. Stringent regulatory
standards governing the biopharmaceutical industry have contributed to the
market's growth. Compliance with Good Manufacturing Practices (GMP) and other
regulatory requirements is essential for biopharmaceutical manufacturers. As a
result, companies invest in advanced fermentation systems to ensure product
quality and regulatory compliance.
In addition, emerging markets, particularly in the Asia-Pacific and Latin America, are witnessing increased biopharmaceutical
production. This trend is driven by economic growth, improved healthcare
infrastructure, and a rising middle-class population. As production scales up
in these regions, so does the demand for fermentation systems.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Biopharmaceutical
Fermentation System Market”
The COVID-19 pandemic has significantly influenced the biopharmaceutical fermentation market. The outbreak led to an
unprecedented surge in demand for enzymes crucial for cutting-edge
point-of-care diagnostic kits and mRNA vaccines. A notable example is a MassBio report from December 2022, which highlighted how the pandemic intensified demand for complex fermentation products in the pharmaceutical and
biotechnology sectors worldwide. The global community relied heavily on enzyme supplies produced by fermentation during this period. Moreover, the
pandemic spurred the development of new biologic drugs for the treatment of COVID-19, thereby amplifying its impact on market growth. For instance, in December 2021, Samsung
Biologics and AstraZeneca expanded their strategic biopharmaceutical production
partnership to include COVID-19 therapies. Additionally, the emergence of
new viral variants has accelerated vaccine production, which involves crucial
fermentation steps. In July 2022, CEPI allocated USD 30 million to clinical trials of a new nanoparticle vaccine designed to protect against a
range of coronaviruses. These initiatives indicate that the studied market is
poised for growth and recovery in the upcoming years.
Furthermore, market growth is driven by the growing demand for biotech-based drugs and increased research and development activities aimed at developing novel biological drugs. For
instance, AbbVie's 2021 annual report highlighted the substantial success of Humira, one of the world's top-selling biologic drugs, which accounted for USD 20.7 billion in net revenue and approximately 37% of AbbVie's total net revenue in 2021. Globally, Humira sales increased by 4% in 2021 compared with the previous year. Similarly, Merck & Co's 2021 annual report noted that
sales of Keytruda, a major biotech-based drug for the company, grew by 20% to
USD 17.2 billion, up from USD 14.9 billion in 2020. These rising sales figures
for biotech-based drugs reflect increasing market demand for such products, which is expected to drive market growth over the forecast period.
Moreover, companies' growing emphasis on developing innovative biopharmaceuticals is expected to increase demand for fermentation services and products, further driving market expansion. As
evidenced by recent developments, in November 2022, Eikonoklastes Therapeutics,
a preclinical biotech company, partnered with Forge Biologics, a gene
therapy-focused contract development and manufacturing organization. This
collaboration aims to advance Eikonoklastes' AAV-based gene therapy, ET-101,
into clinical trials for the treatment of amyotrophic lateral sclerosis (ALS).
Additionally, in August 2022, Sanofi and Innovent Biologics entered a strategic
collaboration to accelerate the development of two biologic oncology medicines
(tusamitamab ravtansine, SAR444245) and expand their presence in China, further
illustrating the momentum in the development of novel biological drugs and its
positive impact on the fermentation market.
The Global Biopharmaceutical Fermentation System Market
is segmented into product type, application, end user, regional distribution,
and company
Based on its product type, the chromatography segment is projected to exhibit a substantial CAGR over the forecast period. This growth is
driven by factors such as the increasing demand for innovative
biopharmaceutical drugs and the introduction of new product offerings.
The launch of new devices increases product availability in the market, thereby stimulating segment
growth. An example of this is Thermo Fisher Scientific's introduction of the
Thermo Scientific HyPeak Chromatography System in October 2021. This system is
among the pioneering single-use chromatography systems for bioprocessing,
offering a broad operational flow range from 1 LPH to 1,980 LPH, achieved through a combination of pumps and fluid transfer assemblies (FTAs) that enable
scalability from process development to cGMP manufacturing. Another noteworthy
release in October 2021 was Novasep's Hipersep Process M, an HPLC
chromatography system designed for the purification of pharmaceutical molecules, including peptides, oligonucleotides, insulin, and other synthetic compounds.
Based on application, the Recombinant Proteins segment
is poised to claim a substantial market share in the Global Biopharmaceutical
Fermentation System Market during the forecast period for several compelling
reasons. First and foremost, there is a growing demand for recombinant proteins
in various therapeutic applications, driven by their efficacy and potential in
treating a wide range of medical conditions. Moreover, advances in biotechnology and genetic engineering have significantly enhanced the production of recombinant proteins via biopharmaceutical fermentation systems, thereby making
them more accessible and cost-effective. Additionally, the expansion of the
biopharmaceutical industry and increasing investment in research and development have accelerated the development of novel recombinant protein-based drugs, further boosting demand for biopharmaceutical
fermentation systems. These factors collectively position the Recombinant
Proteins segment as a prominent player in the biopharmaceutical fermentation
market.
Major companies operating in Global Biopharmaceutical
Fermentation System Market are:
- Agilent Technologies, Inc.
- Thermo Fisher Scientific Inc
- Lonza Group AG
- Sartorius Stedim Biotech GmbH
- Eppendorf SE
- Danaher Corp
- F Hoffmann-La Roche AG
- Nova Biomedical Corp
- Merck KGaA
- Becton Dickinson & Co
Download
Free Sample Report
Customers can also request for 10%
free customization on this report
“The global biopharmaceutical fermentation system
market is in the midst of a significant transformation, driven by a convergence
of technological advancements, changing therapeutic landscapes, and
sustainability concerns. These emerging trends are reshaping the way
biopharmaceuticals are produced and setting the stage for a more efficient,
flexible, and sustainable future. As the industry continues to evolve,
companies that embrace these trends and invest in cutting-edge fermentation
systems will be better positioned to meet the growing demand for
biopharmaceuticals and drive innovation in the field. Staying ahead of these
trends will be key for manufacturers and stakeholders in the biopharmaceutical
fermentation system market,” said Mr. Karan Chechi, Research Director with
TechSci Research, a research-based management consulting firm.
“Biopharmaceutical Fermentation System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Upstream Products (Bioreactors/Fermentors, Bioprocess Analyzers, Process Monitoring System, Others), Downstream Products (Filtration & Separation, Chromatography, Consumables and Accessories, Others)), By Application (Antibiotics, Recombinant Proteins, Others), By End User (Biopharmaceutical Industries, Contract Research Organization, Academic Research Institutes, Others), By Region, and By Competition 2021-2031F”, has evaluated the future growth potential of Global
Biopharmaceutical Fermentation System Market and provides statistics &
information on market size, structure and future market growth. The report aims to provide cutting-edge market intelligence and help decision-makers make sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Biopharmaceutical Fermentation System Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com